During the last session, INmune Bio Inc (NASDAQ:INMB)’s traded shares were 0.34 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $7.52, reflecting an intraday gain of 1.48% or $0.11. The 52-week high for the INMB share is $12.72, that puts it down -69.15 from that peak though still a striking 42.55% gain since the share price plummeted to a 52-week low of $4.32. The company’s market capitalization is $199.97M, and the average intraday trading volume over the past 10 days was 0.3 million shares, and the average trade volume was 381.86K shares over the past three months.
INmune Bio Inc (NASDAQ:INMB) trade information
INmune Bio Inc (INMB) registered a 1.48% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.48% in intraday trading to $7.52, hitting a weekly high. The stock’s 5-day price performance is -7.39%, and it has moved by -4.20% in 30 days. Based on these gigs, the overall price performance for the year is -36.70%. The short interest in INmune Bio Inc (NASDAQ:INMB) is 5.58 million shares and it means that shorts have 22.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 65.82% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $22 and $22 respectively. As a result, INMB is trading at a discount of -192.55% off the target high and -192.55% off the low.
INmune Bio Inc (INMB) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.07%. While earnings are projected to return 14.06% in 2025, the next five years will return 14.21% per annum.
INMB Dividends
INmune Bio Inc is due to release its next quarterly earnings on 2025-Mar-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
INmune Bio Inc (NASDAQ:INMB)’s Major holders
INmune Bio Inc insiders own 23.96% of total outstanding shares while institutional holders control 23.87%, with the float percentage being 31.39%. BLACKROCK INC. is the largest shareholder of the company, while 99.0 institutions own stock in it. As of 2024-06-30, the company held over 0.81 million shares (or 4.2103% of all shares), a total value of $7.17 million in shares.
The next largest institutional holding, with 0.63 million shares, is of VANGUARD GROUP INC’s that is approximately 3.4854% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.54 million.
Also, the Mutual Funds coming in first place with the largest holdings of INmune Bio Inc (INMB) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 434.27 shares. This amounts to just over 1.63 percent of the company’s overall shares, with a $3.27 million market value. The same data shows that the other fund manager holds slightly less at 339.71, or about 1.28% of the stock, which is worth about $2.55 million.
